

Now Enrolling Patients with IgAN in the Phase 3 PROTECT Study

Immunoglobulin A Nephropathy (IgAN) is a rare, chronic kidney disease. IgA is a protein made by the immune system to protect the body from viruses and bacteria. When IgA deposits build up in the kidneys they cause inflammation and damage. This causes the kidneys to leak blood and protein into the urine (proteinuria) and with time, can eventually lead to kidney failure requiring dialysis and/or a kidney transplant. Currently, there are no medications approved specifically for the treatment of IgAN.

About Sparsentan

Sparsentan is an investigational study drug. It has NOT been approved for the treatment of IgAN, or any other disease.

About the PROTECT Study

Traverse Therapeutics is now enrolling patients in the PROTECT Study, a global Phase 3 clinical study investigating the safety of sparsentan and the effects it has on the amount of protein in the urine (proteinuria) and on kidney function in patients with IgAN.

STUDY GOALS



The goals of the study are to evaluate the safety and effectiveness of sparsentan in patients with IgAN.

PATIENT ENROLLMENT



Approximately 380 people will participate at ~170 study sites, globally

STUDY DRUGS



Participants will receive either the investigational study drug sparsentan or irbesartan, one of the drugs commonly used to treat IgAN. Both medications are capsules that are swallowed and are not placebos.

STUDY LENGTH



The study which compares sparsentan to irbesartan will last 2 years and 3 months. Afterwards, in the next phase, eligible patients have the option to take sparsentan.



- Are 18 years old or older
- Have IgAN diagnosed through biopsy
- Have test results that show:
 - the amount of protein in your urine
 - how well your kidneys are working
- Are not on dialysis and have not had a transplant

For more information, visit iganprotect.com, clinicaltrials.gov (NCT03762850), clinicaltrialsregister.eu (EudraCT: 2017-004605-41), kidneyhealthgateway.com or contact medinfo@traverse.com

Talk with your doctor and family members about joining the PROTECT study.
Sites are open and currently recruiting.

